Odd Twist in Phase 3 Alzheimer's Trial for Novel Tau Inhibitor

Although the novel tau aggregation inhibitor hydromethylthionine mesylate did not reach its coprimary endpoints, investigators insist there's more to the story ― especially with the control agent used.
Medscape Medical News

source https://www.medscape.com/viewarticle/984863?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?